|Articles|October 1, 2003

Biopharmaceutical Agents for Treating Rheumatoid Arthritis: Impact on Patients and Managed Care Heal
Volume 9
Issue 6 Suppl

Treatment Compliance and Dosage Administration Among Rheumatoid Arthritis Patients Receiving Infliximab, Etanercept, or Methotrexate

Author(s)Carolyn R. Harley, PhD, Jennifer R. Frytak, PhD, Neeta Tandon, MA

Download PDF: Treatment Compliance and Dosage Administration Among Rheumatoid Arthritis Patients Receiving Infliximab, Etanercept, or Methotrexate

Articles in this issue

almost 23 years ago

Article

Participating Faculty

almost 23 years ago

Article

Defining and Characterizing the Late-stage Biopharmaceutical Pipeline

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

Treatment Compliance and Dosage Administration Among Rheumatoid Arthritis Patients Receiving Infliximab, Etanercept, or Methotrexate

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues

Female Newborns More Likely to Miss Vitamin K Prophylaxis, Hepatitis B Birth Dose

FDA Approved At-Home SC Lecanemab Initiation Dose for Early Alzheimer Disease

Medicaid Fraud Crackdown Intensifies, But Is It Solving the Right Problem?

Provider Trust, Social Media Use Can Shape Vaccine Myth Belief

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Treatment Compliance and Dosage Administration Among Rheumatoid Arthritis Patients Receiving Infliximab, Etanercept, or Methotrexate

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues

Female Newborns More Likely to Miss Vitamin K Prophylaxis, Hepatitis B Birth Dose

FDA Approved At-Home SC Lecanemab Initiation Dose for Early Alzheimer Disease

Medicaid Fraud Crackdown Intensifies, But Is It Solving the Right Problem?

Provider Trust, Social Media Use Can Shape Vaccine Myth Belief